Incyte Corporation Earnings Recaps
Shares were nearly flat after earnings, down 0.1%. Incyte reported 14% revenue growth and broad-based product sales growth, while Jakafi sales grew more slowly than underlying demand amid pricing dynamics.
Key takeaways
- Total revenue was $1.56 billion, up 14% year over year; total net sales were $1.32 billion, also up 14%.
- Jakafi net sales rose 4% to $827 million, while underlying demand increased 12%; the company cited expected pricing dynamics, including the CMS GENEROUS Model.
- Core net sales excluding Jakafi were $490 million, up 30%. OPZELURA sales increased 36% to $255 million, or 21% on a pro forma basis adjusting for a prior-year Medicaid line-extension settlement.
- The company said Jakafi formulary coverage is expected to exceed 80% by year-end and maintained its goal of retaining 10%–30% of the Jakafi business by 2029.
- Incyte cited ongoing reviews for frontline MONJUVI and povorcitinib in HS, and expects first-line MF data for 989 by year-end.
Shares climbed 3.5% post-earnings as solid 20% net sales growth, broad portfolio momentum, and pipeline advancement outpaced investor expectations. Management also unveiled multiple upcoming product launches and a refreshed executive team, supporting confidence in the company’s growth transition beyond Jakafi.
Key takeaways
- First quarter revenue reached $1.27 billion, up 21% year-over-year, with net sales of $1.1 billion (+20%).
- Double-digit growth across all marketed products: Jakafi sales rose 7%, while the core business excluding Jakafi jumped 63% year-over-year.
- The company expects four new product launches within 12 months, including Jakafi XR (anticipated mid-year), Opzelura (European AD), Monjuvi (first-line DLBCL), and povorcitinib (HS).
- Positive late-stage pipeline momentum: FDA accepted povorcitinib application for HS ahead of schedule; Phase III studies underway in hematology, oncology, and immunology.
- Recent executive appointments—including a new CFO and expanded commercial leadership—aim to strengthen operational execution and launch readiness for 2026 and beyond.
Incyte reported a strong Q3 2025, with total revenues of $1.37 billion and product sales of $1.15 billion, reflecting year-over-year growth of 20% and 19%, respectively, driven by robust demand for Jakafi and Opzelura.
Key takeaways
- Jakafi sales reached $791 million, a 7% increase, with broad-based growth across all indications and market share leadership maintained in MF.
- Opzelura achieved $188 million in sales, up 35% year-over-year, bolstered by strong prescription demand and improved formulary access.
- Niktimvo exceeded launch expectations with $46 million in Q3 sales, capturing 13% of the third-line GVHD opportunity shortly after launch.
- Incyte raised its full-year guidance for Jakafi to $3.05 billion to $3.075 billion based on current momentum.
- Upcoming product launches in 2026 are positioned to enhance growth prospects, including ruxolitinib XR and additional indications for Opzelura.
Incyte's Q2 2025 results reflect strong product performance and promising pipeline advancements, positioning the company for sustained growth despite leadership transition and strategic realignment.
Key takeaways
- Opzelura and Niktimvo are demonstrating solid sales momentum, with Opzelura expanding its prescriber base significantly and showing potential for new indications.
- The company is actively focusing on accelerating product development, particularly for the promising asset 989, which targets specific mutations in hematological malignancies.
- Incyte's robust R&D capabilities coupled with a strategic emphasis on capital allocation aim to enhance shareholder value and foster new product growth through both internal development and judicious business development opportunities.